Abstract: The present invention relates to: a therapeutic composition for coronavirus comprising, as an active ingredient, one peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 6, and SEQ ID NO: 8 that binds to a coronavirus N-protein, a coronavirus-derived spike protein, or a fragment of the spike protein; and a composition that binds to a coronavirus N-protein comprising, as an active ingredient, the coronavirus-derived spike protein or the fragment of the spike protein. It is suggested that the peptides of the present invention, based on the understanding and targeting of the interaction of the coronavirus S protein and N protein of the present invention, have an effect that can be helpful in the treatment of coronaviruses including MERS-CoV, SARS-CoV-2, SARS-CoV, and HCoV-OC43.

Abstract: SARS-CoV-2 inhibitors include pharmaceutical compounds capable of binding to the active site of SARS-CoV-2 Mpro. The SARS-CoV-2 inhibitors may be used in pharmaceuticals to prevent and/or treat SARS-CoV-2 infection. The pharmaceuticals may be formulated to comprise at least one SARS-CoV-2 inhibitor and a carrier, or they may include at least one SARS-CoV-2 inhibitor and a further pharmaceutical compound known to be effective against SARS-CoV-2.

Abstract: Anti-SARS-CoV-2 fusion peptides are provided. The anti-SARS-CoV-2 fusion peptides include peptide sequences corresponding to the sequence of the SARS-CoV-2 fusion complex heptad repeat domain HR2 and having at least one artificial mutation. The anti-SARS-CoV-2 fusion peptides may be 39-mers, such as peptides #121 (SEQ ID NO: 2) and #125 (SEQ ID NO: 5). These peptides may competitively bind to SARS-CoV-2 and prevent either membrane mediated SARS-CoV-2 fusion, endocytosis-mediated viral entry, or both. The anti-SARS-CoV-2 fusion peptides may be administered to a subject in need thereof to inhibit or prevent SARS-CoV-2 cellular entry.

Abstract: Anti-SARS-CoV-2 fusion peptides are provided. The anti-SARS-CoV-2 fusion peptides include peptide sequences corresponding to the sequence of the SARS-CoV-2 fusion complex heptad repeat domain HR2 and having at least one artificial mutation. The anti-SARS-CoV-2 fusion peptides may be 39-mers, such as peptides #121 (SEQ ID NO: 2) and #125 (SEQ ID NO: 5). These peptides may competitively bind to SARS-CoV-2 and prevent either membrane mediated SARS-CoV-2 fusion, endocytosis-mediated viral entry, or both. The anti-SARS-CoV-2 fusion peptides may be administered to a subject in need thereof to inhibit or prevent SARS-CoV-2 cellular entry.

Abstract: The present invention relates to a vaccine composition comprising cyclic peptides of the present invention, antibodies to cyclic peptides, or an anticancer composition comprising them, and the vaccine composition of the present invention exhibit an inhibitory activity for metastasis of cancer. In addition, the antibodies of the present invention bind to the tumor-specific antigen TM4SF5 with high affinity, and significantly inhibit the growth, metastasis and invasion of cancer cells expressing the tumor-specific antigen TM4SF5, and thus can be used for diagnosis, prevention or treatment of various cancers expressing TM4SF5.

Abstract: The MERS-CoV inhibitor peptides include a set of peptides designed by modification or mutation of a wild type MERS-CoV fusion protein. The MERS-CoV inhibitor peptides are capable of inhibition of MERS-CoV membrane fusion, and thereby may prevent or slow the spread of MERS-CoV infections. Thus, the MERS-CoV inhibitor peptides may be used in pharmaceuticals to prevent and/or treat MERS-CoV infection. The pharmaceuticals may be formulated to comprise at least one of the MERS-CoV inhibitor peptides and a carrier, or they may include one or more expression systems capable of promoting cellular expression of one or more MERS-CoV inhibitor peptides. The MERS-CoV inhibitor peptides may also be used as reagents for MERS-CoV inhibition assays as a standard or reference inhibitors.

Abstract: The present invention relates to a monoclonal antibody specifically recognizing a spike protein of MERS coronavirus (MERS-CoV) or a part of the protein, or a functional fragment thereof, wherein the monoclonal antibody, or functional fragment of the monoclonal antibody characterized in that it comprises polypeptide sequence selected from the group consisting of the following polypeptide sequences: a heavy chain comprising a complementarity determining region 1(CDR 1) amino acid sequence consisting of the sequence of SEQ ID NO: 1, a CDR2 consisting of the sequence of SEQ ID NO: 2 and a CDR 3 consisting of the sequence of SEQ ID NO: 3; and a light chain comprising CDR1 amino acid sequence consisting of the sequence of SEQ ID NO: 4, a CDR2 consisting of the sequence of SEQ ID NO: 5 and a CDR 3 consisting of the sequence of SEQ ID NO: 6.and uses thereof.

Abstract: The MERS-CoV inhibitor peptides include a set of peptides designed by modification or mutation of a wild type MERS-CoV fusion protein. The MERS-CoV inhibitor peptides are capable of inhibition of MERS-CoV membrane fusion, and thereby may prevent or slow the spread of MERS-CoV infections. Thus, the MERS-CoV inhibitor peptides may be used in pharmaceuticals to prevent and/or treat MERS-CoV infection. The pharmaceuticals may be formulated to comprise at least one of the MERS-CoV inhibitor peptides and a carrier, or they may include one or more expression systems capable of promoting cellular expression of one or more MERS-CoV inhibitor peptides. The MERS-CoV inhibitor peptides may also be used as reagents for MERS-CoV inhibition assays as a standard or reference inhibitors.

Abstract: The present invention relates to in a monoclonal antibody produced by CpG-DNA, or a functional fragment thereof, the monoclonal antibody, or functional fragment thereof, characterized in that it comprises polypeptide sequence selected from the group consisting of the following polypeptide sequences a heavy chain comprising a complementarity determining region 1 (CDR 1) amino acid sequence consisting of the sequence of SEQ ID NO: 1, a CDR2 consisting of the sequence of SEQ ID NO: 2 and a CDR 3 consisting of the sequence of SEQ ID NO: 3; and a light chain comprising CDR1 amino acid sequence consisting of the sequence of SEQ ID NO: 4, a CDR2 consisting of the sequence of SEQ ID NO: 5 and a CDR 3 consisting of the sequence of SEQ ID NO: 6 and a use of the same.

Abstract: According to the present invention, in some embodiments, since a first resin, a first fabric and a second resin are layered and coupled to each other and the first resin and the second resin are coupled by through-holes of the first fabric, the first resin and the second resin are uniformly absorbed and coated on the surface of the first fabric, and the first resin, the first fabric, and the second resin are closely coupled to each other, thereby enabling a unique color of the first fabric to be displayed on the exterior, a travel bag having very excellent compactness, tensile strength and impact strength to be manufactured, a travel bag having excellent quality to be provided even if manufacturing costs and manufacturing processes are decreased, and a travel bag capable of maximizing user convenience and the operability of the travel bag by remarkably reducing the weight to be provided.

Abstract: The present invention relates to a vaccine composition comprising cyclic peptides of the present invention, antibodies to cyclic peptides, or an anticancer composition comprising them, and the vaccine composition of the present invention exhibit an inhibitory activity for metastasis of cancer. In addition, the antibodies of the present invention bind to the tumor-specific antigen TM4SF5 with high affinity, and significantly inhibit the growth, metastasis and invasion of cancer cells expressing the tumor-specific antigen TM4SF5, and thus can be used for diagnosis, prevention or treatment of various cancers expressing TM4SF5.

Abstract: The present invention provides an antibody or antigen binding fragment thereof, that binds to TM4SF5, and uses thereof. The antibody of this invention inhibits the growth, metastasis and invasion of cancer cells expressing TM4SF5 by binding to a tumor-specific antigen, TM4SF5, with high affinity, and therefore can be used to diagnose, prevent or treat various cancers expressing TM4SF5.

Abstract: The present invention provides an antibody or antigen binding fragment thereof, that binds to TM4SF5, and uses thereof. The antibody of this invention inhibits the growth, metastasis and invasion of cancer cells expressing TM4SF5 by binding to a tumor-specific antigen, TM4SF5, with high affinity, and therefore can be used to diagnose, prevent or treat various cancers expressing TM4SF5.

Abstract: The present invention relates to a composition for enhancing an immune response, an epitope having immunogenicity, screening and preparing method thereof, a antibody to peptide antigen and screening and preparing method thereof. The composition of the present invention may be effectively used for preventing or treating diverse immune-deficiency diseases such as cancer, influenza virus, hepatitis C virus and RSV (respiratory syncytial virus) by enhancing immune responses.

Abstract: The present invention relates to a composition for enhancing an immune response, an epitope having immunogenicity, screening and preparing method thereof, a antibody to peptide antigen and screening and preparing method thereof. The composition of the present invention may be effectively used for preventing or treating diverse immune-deficiency diseases such as cancer, influenza virus, hepatitis C virus and RSV (respiratory syncytial virus) by enhancing immune responses.

Abstract: The present invention relates to a composition for enhancing an immune response, an epitope having immunogenicity, screening and preparing method thereof, a antibody to peptide antigen and screening and preparing method thereof. The composition of the present invention may be effectively used for preventing or treating diverse immune-deficiency diseases such as cancer, influenza virus, hepatitis C virus and RSV (respiratory syncytial virus) by enhancing immune responses.

Abstract: The present invention relates to a composition for enhancing an immune response, an epitope having immunogenicity, screening and preparing method thereof, a antibody to peptide antigen and screening and preparing method thereof. The composition of the present invention may be effectively used for preventing or treating diverse immune-deficiency diseases such as cancer, influenza virus, hepatitis C virus and RSV (respiratory syncytial virus) by enhancing immune responses.

Abstract: Disclosed is a bag having a handle unit with improved precision of an extendable length. The bag includes a body and a handle unit mounted on one side of the body. The handle unit includes a housing coupled with one side of the body and having an installation space therein, a foldable section arranged in the installation space and having a configuration in which a plurality of links cross each other such that the plurality of links are extended and contracted in folded or unfolded states, a lock gear section that fixes an extendable length of the foldable section and is coupled to an upper end of the foldable section to reduce tolerance occurring when the foldable section is extended and contracted, and a lock gear adjustment section that adjusts driving of the lock gear section such that the foldable section.

Abstract: Disclosed is the therapeutic use of CpG oligodeoxynucleotides for skin diseases. The CpG oligodeoxynucleotides (CpG ODNs) of the present invention show excellent immunoactive effects against skin diseases in both cases of CpG ODNs with a phosphorothioate backbone and CpG ODNs with a phosphodiester backbone.

Abstract: Disclosed is a foldable cross-patterned pull-handle and a bag having the same. The pull-handle includes a folding means having a first link assembly and a second link assembly connected to an end of the first link assembly so that the folding means can be folded and retracted or unfolded and extended, the first link assembly having two links connected to each other so that the links cross each other at a center portion, a first end of the second link assembly being supported on a bag; and a handle means mounted on a second end of the folding means and grabbed by a user with hand. Due to the structural characteristics of the link assemblies constituting the folding means, the length of the bag handle can be adjusted variously by folding or unfolding it, and the bag handle can be installed in a reduced space.